Cargando…

Higher rates of HBsAg clearance with tenofovir-containing therapy in HBV/HIV co-infection

INTRODUCTION: Achieving functional cure of chronic HBV infection (Hepatitis B surface antigen [HBsAg] clearance, eventually followed by acquisition of anti-hepatitis B surface antigen [Anti-HBs]) in individuals with HIV and HBV infections is a rare event. In this setting, factors related to HBV cure...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gantner, Pierre, Cotte, Laurent, Allavena, Clotilde, Bani-Sadr, Firouzé, Huleux, Thomas, Duvivier, Claudine, Valantin, Marc-Antoine, Jacomet, Christine, Joly, Véronique, Chéret, Antoine, Pugliese, Pascal, Delobel, Pierre, Cabié, André, Rey, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6472771/ https://www.ncbi.nlm.nih.gov/pubmed/30998789 http://dx.doi.org/10.1371/journal.pone.0215464

Ejemplares similares

Incidence of cervical, breast and colorectal cancers between 2010 and 2015 in people living with HIV in France
por: Rojas Rojas, Teresa, et al.
Publicado: (2022)

Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination
por: Virlogeux, Victor, et al.
Publicado: (2017)

Derivation and internal validation of a mortality risk index for aged people living with HIV: The Dat'AIDS score
por: Hentzien, Maxime, et al.
Publicado: (2018)

Effectiveness and tolerance of single tablet versus once daily multiple tablet regimens as first-line antiretroviral therapy - Results from a large french multicenter cohort study
por: Cotte, Laurent, et al.
Publicado: (2017)

Efficacy and tolerability of Etravirine in HIV-1 adult patients: Results of a large French prospective cohort
por: Allavena, Clotilde, et al.
Publicado: (2014)

Comparative Effectiveness of First Antiretroviral Regimens in Clinical Practice Using a Causal Approach
por: Cuzin, Lise, et al.
Publicado: (2015)

Antiretroviral exposure and comorbidities in an aging HIV-infected population: The challenge of geriatric patients
por: Allavena, Clotilde, et al.
Publicado: (2018)

Long-term efficacy and toxicity of abacavir/lamivudine/nevirapine compared to the most prescribed ARV regimens before 2013 in a French Nationwide Cohort Study
por: de Boissieu, Paul, et al.
Publicado: (2016)

Antiretroviral therapy as a risk factor for chronic kidney disease: Results from traditional regression modeling and causal approach in a large observational study
por: Cuzin, Lise, et al.
Publicado: (2017)

Kaposi sarcoma among people living with HIV in the French DAT’AIDS cohort between 2010 and 2015
por: Poizot‐Martin, I., et al.
Publicado: (2020)

Coexistence of HBsAg and HBsAb in a difficult-to-treat chronic hepatitis B: loss of HBsAg with entecavir plus tenofovir combination
por: Galati, Giovanni, et al.
Publicado: (2014)

Potential for Drug-Drug Interactions between Antiretrovirals and HCV Direct Acting Antivirals in a Large Cohort of HIV/HCV Coinfected Patients
por: Poizot-Martin, Isabelle, et al.
Publicado: (2015)

Comparison of Serum HBsAg Quantitation by Four Immunoassays, and Relationships of HBsAg Level with HBV Replication and HBV Genotypes
por: Tuaillon, Edouard, et al.
Publicado: (2012)

High syphilis prevalence and incidence in people living with HIV and Preexposure Prophylaxis users: A retrospective review in the French Dat’AIDS cohort
por: Lemmet, Thomas, et al.
Publicado: (2022)

Performance Evaluation of an Improved HBsAg Assay (HBsAg NEXT) for the Detection of HBsAg Levels
por: Gupta, Ekta, et al.
Publicado: (2023)

Hepatitis C treatment initiation in HIV-HCV coinfected patients
por: Cotte, Laurent, et al.
Publicado: (2016)

Dilemma of HBsAg seroconversion in chronic hepatitis B infection: Dilemma of HBsAg in chronic HBV
por: Alavian, Seyed Moayed, et al.
Publicado: (2011)

The potential effect of HBV vaccination on off-treatment HBsAg reversion after interferon-induced HBsAg clearance
por: Jiang, Shaowen, et al.
Publicado: (2023)

Kinetics in HBsAg after Stopping Entecavir or Tenofovir in Patients with Virological Relapse but Not Clinical Relapse
por: Tseng, Tzu-Ning, et al.
Publicado: (2022)

HIV-related excess mortality and age-related comorbidities in patients with HIV aged ≥60: a relative survival analysis in the French Dat’AIDS cohort
por: Hentzien, Maxime, et al.
Publicado: (2019)

Too fast to stay on track? Shorter time to first anti-retroviral regimen is not associated with better retention in care in the French Dat’AIDS cohort
por: Cuzin, L., et al.
Publicado: (2019)

First-line cART regimen impacts the course of CD8(+) T-cell counts in HIV-infected patients that achieve sustained undetectable viral load.
por: Poizot-Martin, Isabelle, et al.
Publicado: (2016)

Comparison of the Clinical Features of Hepatitis A between HBsAg-Positive and HBsAg-Negative Patients
por: Kim, Kwang Min, et al.
Publicado: (2011)

What are the causes and outcomes of the coexistence of HBsAg and anti-HBs?
por: Afyon, Murat
Publicado: (2016)

Paradoxical HBsAg and anti-HBs coexistence among Chronic HBV Infections: Causes and Consequences
por: Jiang, Xinyi, et al.
Publicado: (2021)

CMV+ Serostatus Associates Negatively with CD4:CD8 Ratio Normalization in Controlled HIV-Infected Patients on cART
por: Poizot-Martin, Isabelle, et al.
Publicado: (2016)

A Hyper-Glycosylation of HBV Surface Antigen Correlates with HBsAg-Negativity at Immunosuppression-Driven HBV Reactivation in Vivo and Hinders HBsAg Recognition In Vitro
por: Salpini, Romina, et al.
Publicado: (2020)

Contribution of NK cells to HBsAg seroconversion in inactive HBsAg carriers following pegylated IFN therapy
por: Cao, Zhenhuan, et al.
Publicado: (2020)

Comparative analysis of the safety and efficacy of HBsAg-1018 versus HBsAg-Eng: a meta-analysis
por: ZHANG, LIN L., et al.
Publicado: (2020)

B cells were related to HBsAg seroconversion in inactive HBsAg carriers following peginterferon therapy
por: Cao, Zhenhuan, et al.
Publicado: (2020)

Long-term outcomes of HBsAg/anti-HBs double-positive versus HBsAg single-positive patients with chronic hepatitis B
por: Kwak, Min-Sun, et al.
Publicado: (2019)

Dynamic changes of HBV markers and HBV DNA load in infants born to HBsAg(+) mothers: can positivity of HBsAg or HBV DNA at birth be an indicator for HBV infection of infants?
por: Chen, Tianyan, et al.
Publicado: (2013)

Missed opportunities of HIV pre-exposure prophylaxis in France: a retrospective analysis in the French DAT’AIDS cohort
por: Lions, C., et al.
Publicado: (2019)

Switching to PegIFNα-2b leads to HBsAg loss in patients with low HBsAg levels and HBV DNA suppressed by NAs
por: Huang, Jing, et al.
Publicado: (2017)

Key mutations in the C-terminus of the HBV surface glycoprotein correlate with lower HBsAg levels in vivo, hinder HBsAg secretion in vitro and reduce HBsAg structural stability in the setting of HBeAg-negative chronic HBV genotype-D infection
por: Salpini, Romina, et al.
Publicado: (2020)

Assessment of noninvasive liver stiffness in inactive HBsAg carriers by transient elastography: Fibroscan in inactive HBsAg carriers
por: Sporea, Ioan, et al.
Publicado: (2011)

Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro
por: Salpini, Romina, et al.
Publicado: (2017)

Clinical cure rate of inactive HBsAg carriers with HBsAg <200 IU/ml treated with pegylated interferon
por: Li, Hong, et al.
Publicado: (2022)

The role of HBsAg levels in the current management of chronic HBV infection
por: Höner zu Siederdissen, Christoph, et al.
Publicado: (2014)

Prediction Model of HBsAg Seroclearance in Patients with Chronic HBV Infection
por: Cao, Jing, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ot8c1bom863m7tl6v5og1clba2